[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1332-1348.
[2] World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016-2021[R]. Geneva: World Health Organization, 2019.
[3] Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119.
[4] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[5] Popescu M S, Firu D M, Mitruţ R, et al. Metabolic impact of diabetes mellitus type 2 in hepatitis C virus infected patients[J]. Curr Health Sci J, 2021, 47(3): 405-411.
[6] Million Y, Teklu T, Alemu S, et al. Hepatitis B and hepatitis C viral infections and associated factors among patients with diabetes visiting gondar referral teaching hospital, northwest ethiopia: a comparative cross-sectional study[J]. J Hepatocell Carcinoma, 2019, 6: 143-150.
[7] Farshadpour F, Taherkhani R, Ravanbod M R, et al. Prevalence and genotype distribution of hepatitis C virus infection among patients with type 2 diabetes mellitus[J]. Med Princ Pract, 2018, 27(4): 308-316.
[8] Fabiani S, Fallahi P, Ferrari S M, et al. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature[J]. Rev Endocr Metab Disord, 2018, 19(4): 405-420.
[9] Chen Y, Ji H, Shao J, et al. Different hepatitis C virus infection statuses show a significant risk of developing type 2 diabetes mellitus: a network meta-analysis[J]. Dig Dis Sci, 2020, 65(7): 1940-1950.
[10] Kuna L, Jakab J, Smolic R, et al. HCV extrahepatic manifestations[J]. J Clin Transl Hepatol, 2019, 7(2): 172-182.
[11] Makvandi M, Azaran A, Jalilian S, et al. Frequency and genotype distribution of hepatitis C virus infection in patients with diabetes type 2 in Ahvaz, Iran[J]. Iran J Microbiol, 2021, 13(5): 703-711.
[12] Banerjee S, Saito K, Ait-Goughoulte M, et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance[J]. J Virol, 2008, 82(6): 2606-2612.
[13] Ciardullo S, Mantovani A, Ciaccio A, et al. Hepatitis C virus infection and diabetes: a complex bidirectional relationship[J]. Diabetes Res Clin Pract, 2022, 187: 109870.
[14] Knobler H, Zhornicky T, Sandler A, et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association[J]. Am J Gastroenterol, 2003, 98(12): 2751-2756.
[15] Tawadrous G A, Aziz A A, Amin D G, et al. RANTES, TNF-α, oxidative stress, and hematological abnormalities in hepatitis C virus infection[J]. J Investig Med, 2012, 60(6): 878-882.
[16] Serfaty L. Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia[J]. Clin Liver Dis, 2017, 21(3): 475-486.
[17] Amako Y, Munakata T, Kohara M, et al. Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression[J]. J Virol, 2015, 89(8): 4092-4101.
[18] Chen J, Wang F, Zhou Y, et al. Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38δ MAPK-dependent exocytosis in pancreatic β-cells[J]. Clin Sci (Lond), 2020, 134(5): 529-542.
[19] 姚利璇, 牛奔. 丙型肝炎病毒感染诱发2型糖尿病的相关研究进展[J]. 医学综述, 2022, 28(6): 1186-1192.
[20] Zou D M, Sun W L. Relationship between hepatitis C virus infection and iron overload[J]. Chin Med J (Engl), 2017, 130(7): 866-871.
[21] Zoppini G, Fedeli U, Gennaro N, et al. Mortality from chronic liver diseases in diabetes[J]. Am J Gastroenterol, 2014, 109(7): 1020-1025.
[22] Yen Y H, Kuo F Y, Kee K M, et al. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients[J]. Dig Liver Dis, 2019, 51(1): 142-148.
[23] Zied H Y, Abo Alnasr N M, El-Bendary A S, et al. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4[J]. Diabetes Metab Syndr, 2020, 14(4): 679-682.
[24] Takahashi H, Nakahara T, Kogiso T, et al. Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: a multicenter study[J]. JGH Open, 2020, 5(2): 228-234.
[25] Li J, Gordon S C, Rupp L B, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes[J]. Aliment Pharmacol Ther, 2019, 49(5): 599-608.
[26] Benhammou J N, Moon A M, Pisegna J R, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C[J]. Dig Dis Sci, 2021, 66(7): 2394-2406.
[27] Tsai P C, Kuo H T, Hung C H, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan[J]. J Hepatol, 2023, 78(2): 281-292.
[28] Hsu W H, Sue S P, Liang H L, et al. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a nationwide study in Taiwan[J]. Front Public Health, 2021, 9: 711723.
[29] Su P Y, Chen Y Y, Yen H H, et al. Strategy for the micro-elimination of hepatitis C among patients with diabetes mellitus-A hospital-based experience[J]. J Clin Med, 2021, 10(11): 2509. |
